Alpha 2.0
Login Register
» Authors » Marianna Macerelli

Marianna Macerelli

Explore the profile of Marianna Macerelli including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 25
Citations 592
Followers 0
Related Specialties
Oncology
Pharmacology
Pulmonary Medicine
Top 10 Co-Authors
Diego Signorelli
Marina Chiara Garassino
Monica Ganzinelli
Claudia Proto
Giuseppe Lo Russo
Francesco Grossi
Carlo Genova
Alessio Cortellini
Francesca Mazzoni
Rita Chiari
Published In
Clin Lung Cancer
Crit Rev Oncol Hematol
Tumori
Int J Mol Sci
Ther Adv Med Oncol
Affiliations
Soon will be listed here.
Recent Articles
1.
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry
Cortellini A, Brunetti L, Di Fazio G, Garbo E, Pinato D, Naidoo J, et al.
J Immunother Cancer . 2025 Feb; 13(2). PMID: 39904562
Background: Pembrolizumab monotherapy is an established front-line treatment for advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) tumor proportion score (TPS)≥50%. However, real-world data on its...
2.
Antibody-Drug Conjugates in Non-Small Cell Lung Cancer: State of the Art and Future Perspectives
Zanchetta C, De Marchi L, Macerelli M, Pelizzari G, Costa J, Aprile G, et al.
Int J Mol Sci . 2025 Jan; 26(1. PMID: 39796075
Antibody-drug conjugates (ADCs) represent one of the most promising and rapidly emerging anti-cancer therapies because they combine the cytotoxic effect of the conjugate payload and the high selectivity of the...
3.
The Role of ctDNA in the Management of Non-Small-Cell Lung Cancer in the AI and NGS Era
Costa J, Membrino A, Zanchetta C, Rizzato S, Cortiula F, Rossetto C, et al.
Int J Mol Sci . 2025 Jan; 25(24. PMID: 39769431
Liquid biopsy (LB) involves the analysis of circulating tumour-derived DNA (ctDNA), providing a minimally invasive method for gathering both quantitative and qualitative information. Genomic analysis of ctDNA through next-generation sequencing...
4.
Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World
Pasello G, Lorenzi M, Scattolin D, Del Conte A, Cecere F, Pavan A, et al.
Oncologist . 2024 Mar; 29(7):596-608. PMID: 38520745
Introduction: The observational multicenter prospective FLOWER study (NCT04965701) confirmed effectiveness and safety of osimertinib in the real-world (RW) management of untreated EGFR-mutant advanced non-small cell lung cancer (aNSCLC) patients. Methods:...
5.
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research
Prelaj A, Ganzinelli M, Provenzano L, Mazzeo L, Viscardi G, Metro G, et al.
Clin Lung Cancer . 2024 Jan; 25(2):190-195. PMID: 38262770
Introduction: Despite several therapeutic efforts, lung cancer remains a highly lethal disease. Novel therapeutic approaches encompass immune-checkpoint inhibitors, targeted therapeutics and antibody-drug conjugates, with different results. Several studies have been...
6.
Rare and Insidious Toxicities from New Combination Therapies in Metastatic Renal Cell Cancer: Lessons Learned from Real-Practice
Dri A, Garattini S, Cinausero M, Macerelli M, Fanelli M, Puglisi F, et al.
Curr Oncol . 2022 Oct; 29(10):6776-6786. PMID: 36290810
The advent of immune checkpoint inhibitors in combination with multitarget tyrosine kinase inhibitors has become a standard first-line treatment for metastatic renal cell cancer. Along with survival improvement, new toxicities...
7.
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status
Cortellini A, Giusti R, Filetti M, Citarella F, Adamo V, Santini D, et al.
J Hematol Oncol . 2022 Jan; 15(1):9. PMID: 35062993
Family history of cancer (FHC) is a hallmark of cancer risk and an independent predictor of outcome, albeit with uncertain biologic foundations. We previously showed that FHC-high patients experienced prolonged...
8.
Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy
Banna G, Tiseo M, Cortinovis D, Facchinetti F, Aerts J, Baldessari C, et al.
Thorac Cancer . 2021 Dec; 13(3):483-488. PMID: 34939342
Background: Patients with programmed cell death-ligand 1 (PD-L1) ≥50% metastatic non-small cell lung cancer (mNSCLC) and ECOG performance status (PS) of 2 treated with first-line immunotherapy have heterogeneous clinical assessment...
9.
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy
Cortellini A, Di Maio M, Nigro O, Leonetti A, Cortinovis D, Aerts J, et al.
J Immunother Cancer . 2021 Apr; 9(4). PMID: 33827906
Background: Some concomitant medications including antibiotics (ATB) have been reproducibly associated with worse survival following immune checkpoint inhibitors (ICIs) in unselected patients with non-small cell lung cancer (NSCLC) (according to...
10.
Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial)
Gelsomino F, Lamberti G, Tiseo M, Rocco D, Pasello G, Cecere F, et al.
Ther Adv Med Oncol . 2020 Aug; 12:1758835920915983. PMID: 32733604
Background: Although immunotherapy with immune-checkpoint inhibitors (ICIs) has profoundly changed the therapeutic scenario in the treatment of advanced non-small cell lung cancer (NSCLC), trials of ICIs only enrolled NSCLC patients...